Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Abzena Plc, Medical Devices Deals, 2011 to YTD 2017 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Abzena Raises Funds through Venture Financing 15
PolyTherics Secures US$3.5 Million In Series B Financing 17
Partnerships 18
Abzena Enters into Agreement with Enleofen Bio 18
Abzena Partners with UGA Biopharma 19
Abzena and Baylor Scott & White Research Institute Form Joint Venture 20
Abzena Enters into Agreement with Apitope 21
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 22
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 23
PolyTherics Extends Agreement With MacroGenics To Produce Antibody Drug Conjugates 24
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 25
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 26
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 27
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 28
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 29
Antitope Enters Into Research Agreement With NeuroPhage Pharma 30
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 31
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 32
Antitope Enters Into Research Collaboration With Therapure Biopharma 33
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 34
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 35
Antitope Enters Into Co-Development Agreement With IMMIH 36
Antitope Enters Into Research Collaboration With NasVax 37
Cellmid Enters into Agreement with Antitope 38
PolyTherics Enters Into Drug Development Agreement With Critical Pharma 39
Licensing Agreements 40
Telix Pharma Enters into Licensing Agreement with Abzena 40
OBI Pharma Enters into Licensing Agreement with Abzena 41
Abzena Enters into Licensing Agreement for ThioBridge 42
Trieza Therapeutics Enters into Licensing Agreement with Abzena 43
ProtAb Enters into License Agreement with Antitope 44
Abzena Enters into Licensing Agreement for Thiobridge ADC Linker Technology 45
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 46
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 47
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 48
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 49
Nuron Biotech Exercises Option Licensing Agreement With PolyTherics 50
Equity Offering 51
Abzena Raises USD31 Million in Private Placement of Shares 51
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 52
Abzena Raises USD31.8 Million in Private Placement of Shares 53
Abzena Completes IPO 54
Acquisition 55
Abzena Acquires The Chemistry Research Solution for USD15 Million 55
Abzena Acquires PacificGMP 56
PolyTherics Acquires Antitope For US$20.7 Million 58
Abzena Plc – Key Competitors 59
Abzena Plc – Key Employees 60
Abzena Plc – Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Joint Venture 61
Recent Developments 62
Financial Announcements 62
Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 62
Feb 21, 2017: Abzena: Trading and business update 63
Nov 30, 2016: Abzena announce Half year results: Integrated service offering driving revenue growth 65
Jun 14, 2016: Abzena Announces Full Year Results: Eevenues up 74%, Strong Outlook Within Growing Market 69
Corporate Communications 70
Oct 24, 2016: Abzena makes two senior executive appointments to drive growth of international business 70
Sep 13, 2016: Abzena Announces Directorate change 71
Government and Public Interest 72
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 72
Jan 18, 2016: Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders 73
Other Significant Developments 74
Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article 74
Mar 09, 2016: Abzena provides Business update – strong second half momentum 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Abzena Plc, Deals By Therapy Area, 2011 to YTD 2017 10
Abzena Plc, Medical Devices Deals, 2011 to YTD 2017 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Abzena Raises Funds through Venture Financing 15
PolyTherics Secures US$3.5 Million In Series B Financing 17
Abzena Enters into Agreement with Enleofen Bio 18
Abzena Partners with UGA Biopharma 19
Abzena and Baylor Scott & White Research Institute Form Joint Venture 20
Abzena Enters into Agreement with Apitope 21
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 22
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 23
PolyTherics Extends Agreement With MacroGenics To Produce Antibody Drug Conjugates 24
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 25
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 26
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 27
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 28
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 29
Antitope Enters Into Research Agreement With NeuroPhage Pharma 30
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 31
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 32
Antitope Enters Into Research Collaboration With Therapure Biopharma 33
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 34
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 35
Antitope Enters Into Co-Development Agreement With IMMIH 36
Antitope Enters Into Research Collaboration With NasVax 37
Cellmid Enters into Agreement with Antitope 38
PolyTherics Enters Into Drug Development Agreement With Critical Pharma 39
Telix Pharma Enters into Licensing Agreement with Abzena 40
OBI Pharma Enters into Licensing Agreement with Abzena 41
Abzena Enters into Licensing Agreement for ThioBridge 42
Trieza Therapeutics Enters into Licensing Agreement with Abzena 43
ProtAb Enters into License Agreement with Antitope 44
Abzena Enters into Licensing Agreement for Thiobridge ADC Linker Technology 45
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 46
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 47
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 48
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 49
Nuron Biotech Exercises Option Licensing Agreement With PolyTherics 50
Abzena Raises USD31 Million in Private Placement of Shares 51
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 52
Abzena Raises USD31.8 Million in Private Placement of Shares 53
Abzena Completes IPO 54
Abzena Acquires The Chemistry Research Solution for USD15 Million 55
Abzena Acquires PacificGMP 56
PolyTherics Acquires Antitope For US$20.7 Million 58
Abzena Plc, Key Competitors 59
Abzena Plc, Key Employees 60
Abzena Plc, Subsidiaries 61
Abzena Plc, Joint Venture 61